MAP Pharmaceuticals: PharmaVitae Report

Introduction

This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s historical and forecast financial performance. The report also gives an in-depth analysis of the company’s key prescription pharmaceutical product, and provides a forecast sales performance for this drug.

Features and benefits

• Gain insight into MAP Pharmaceuticals' strategic outlook
• Analyze company sales forecasts by product

Highlights

MAP’s most advanced product candidate is Levadex (dihydroergotamine), an orally inhaled migraine therapy, which represents the main driver for the company. The New Drug Application for Levadex is currently under review by the FDA with an action date of March 26, 2012.

Your key questions answered

• Benchmark MAP Pharmaceuticals' performance against key rivals in the prescription pharmaceutical sector
• Assess how successful MAP Pharmaceuticals will be in obtaining marketing approval for its first product

Table Of Contents

ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Sales and product analysis
Financial analysis
Data sourcing
Analyst consensus

EXECUTIVE SUMMARY
Company introduction
Recent developments
Corporate relationships
Strategic overview
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats

SALES AND PRODUCT ANALYSIS
Sales overview
Product analysis
Product sales
Migraine and the history of dihydroergotamine
Levadex
Key competitors
Clinical trials
Commercial impact of trial results
Key forecasting assumptions
Early-stage products
MAP0001

FINANCIAL ANALYSIS
Financial performance overview
Operating costs and profit analysis, 2004–10
Operating costs and profit analysis, 2010–16

APPENDIX
References
Datamonitor reports
Exchange rates

List Of Tables

Table: MAP Pharmaceuticals product portfolio overview ($m), 2010–16
Table: MAP Pharmaceuticals’ Phase III clinical trial program included one pivotal trial and four safety studies
Table: Levadex US sales forecast model
Table: MAP Pharmaceuticals operating revenue/cost analysis ($m), 2004–10
Table: MAP Pharmaceuticals operating revenue/cost analysis ($m), 2010–16
Table: Exchange rates, 2011

List Of Figures

Figure: PharmaVitae Explorer
Figure: SWAT analysis
Figure: MAP Pharmaceuticals prescription pharmaceutical performance, sales ($m) and growth rate (%), 2010–16
Figure: MAP Pharmaceuticals key product sales ($m), 2010–16
Figure: MAP Pharmaceuticals operating/cost performance ($m), 2004–16